AlphAIAlphAI — Financial news for AI agents
investing.com$HIMS

Hims & Hers earnings missed by $0.20, revenue fell short of estimates

Hims & Hers (HIMS) reported Q3 EPS of -$0.14, missing estimates by $0.20, with revenue at $890.4M, slightly below expectations. The company forecasted Q4 2026 revenue of $875M-$895M, below the consensus of $955.10M, and FY 2026 revenue of $3.13B-$3.15B, below the consensus of $3.21B. The stock is down 20.26% in the last 3 months and 44.12% in the last 12 months, with 6 negative EPS revisions in the last 90 days.

Original reporting
investing.com
Published Nov 9, 2026, 9:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 9:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$HIMS
Bearish
high confidence
Mentioned
$HIMS
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$HIMSBearishHigh
01

Why it matters

The earnings miss may lead to a short‑term decline in HIMS shares, while the guidance gap could extend the downside if investors reassess growth prospects.

02

Market read

New earnings data creates immediate trading opportunity; investors may adjust positions based on the miss and lowered guidance.

03

What to watch

Potential upside from upcoming product launches or cost‑saving initiatives not reflected in the current guidance.

Relevance 7/10Novelty 8/10Timing: after-hours

Background

Hims & Hers reported Q3 results that fell short of analyst expectations on both earnings and revenue, and provided guidance below consensus for the upcoming quarter and full year.

Company-level read

Ticker impact

$HIMSBearishHigh confidence
Context

Q3 EPS of -$0.14 missed estimate by $0.20 and revenue of $890.4M fell short of $892.88M consensus.

Expected impact

downward pressure as market prices in the earnings miss

Evidence & confidence

Both EPS and revenue came in below expectations, and guidance for Q4 and FY2026 is also below consensus, prompting negative sentiment.

Market effects

Sector

Telehealth/consumer health sector may see broader scrutiny as Hims & Hers underperforms expectations.

Regional

U.S. market sentiment could be slightly dampened in the health‑tech niche.

Global

Limited to investors tracking U.S. consumer health stocks; no major global ripple.

Counterpoint

What could challenge this read

If the market overreacts to a modest miss, the stock could rebound on short‑covering.

Key entities

  • company
    Hims & Hers

    U.S.-listed telehealth and consumer health company (NYSE:HIMS).

Read at source← All news

StoryHims & Hers posts 49% revenue growth but margin collapse and cuts 2026 guidance

Also covered by

5 outlets

Related articles

$HIMSMed

HIMS May See Heightened ‘Gyrations’ As Weight-Loss Drug Trends Fuel Subscriber Uncertainty, Jefferies Warns – Stock Hits 7-Month Lows

Hims & Hers Health (HIMS) shares fell 15% after Q3 earnings missed expectations, with subscribers declining sequentially. Jefferies lowered its price target to $24, citing volatility from weight-loss drug trends. Needham reduced its target to $32 but kept a 'Buy' rating. The company reported a Q3 loss and cut its FY2026 EBITDA and revenue guidance.

finance.yahoo.com
$HIMSHighAI 8/10

Hims & Hers Stock Falls 15% on Weak Q4 Revenue Outlook

Hims & Hers Health (HIMS) shares dropped 15% after the company issued Q4 revenue guidance below expectations, forecasting $875M–$895M vs. analysts' $955.1M estimate. Q3 revenue grew 49% to $890.4M but gross margin declined to 57% from 74%. The company also faces regulatory challenges over weight-loss medications and data privacy.

grafa.com
$HIMSHighAI 8/10

Hims & Hers cuts 2026 earnings outlook despite 49% revenue growth

Hims & Hers Health (HIMS) reported 49% revenue growth in Q3, but lowered its 2026 adjusted EBITDA forecast to $257M-$277M. Revenue guidance was tightened to $3.13B-$3.15B, with Q4 sales expected at $875M-$895M. International revenue surged 321%, while gross margin contracted to 57% from 74%. The company reported a net loss of $33M, with adjusted EBITDA margin falling to 9% from 13%.

finance.yahoo.com